Cell Proliferation and Apoptosis in Prostate Cancer - Correlation with Pathologic Stage?

Modern Pathology

Volumn 9, Issue 3, 1996, Pages 205-209

  Brown, Christine ^b   Sauvageot, Jurga ^b   Kahane, Hillel ^b   Epstein, Jonathan I ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

Apoptosis; Gleason grade; Ki 67; Prostate cancer; Stage

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

APOPTOSIS; ARTICLE; CANCER STAGING; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

APOPTOSIS; CARCINOMA; CELL DIVISION; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS;

EID: 0030008147     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy The Johns Hopkins experience after 10 years. Urol Clin North Am 20:4, 1993.
2. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71:11, 1993.
3. Harper ME, Glynne-Jones E, Goddard L, et al.: Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate 20:243, 1992.
4. McLoughlin J, Foster CS, Price P, Williams G, Abel PD: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 72:92, 1993.
5. Harper ME, Goddard L, Wilson DW, et al.: Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 21:75, 1992.
6. Nemoto R, Kawamura H, Miyahawa I, et al.: Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma. J Urol 149:165, 1993.
7. Carroll PR, Waldman FM, Rosenau W, et al.: Cell proliferation in prostatic adenocarcinoma: In vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. J Urol 149:403, 1993.
8. Spires SE, Jennings CD, Banks ER, et al.: Proliferating cell nuclear antigen in prostatic adenocarcinoma: Correlation with established prognostic indicators. Urology 43:660, 1994.
9. Montironi R, Galluzzi CM, Diamanti L, et al.: Prostatic intraepithelial neoplasia: Expression and location of proliferating cell nuclear antigen in epithelial, endothelial, and stromal nuclei. Virchows Archiv A Pathol Anat 422:185, 1993.
10. Gerdes I, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody. J Immuno 133:1710, 1994.
11. Aihara M, Scardino PT, Truong LD, et al.: The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 75:522, 1995.
12. Aihara M, Truong LD, Dunn JK, et al.: Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 25:797, 1994.
13. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493, 1992.
14. Berges RR, Vukanovic J, Epstein JI, et al.: Implications of the cell kinetic changes during the progression of human prostatic cancer. Clin Can Res 1:473, 1995.
15. Epstein JI, Partin AW: Neuroendocrine (NE) differentiation in prostate cancer: Enhanced prediction of progression following radical prostatectomy (abstract). Mod Pathol 8:75A, 1995.